Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Star Bulk Carriers Corp (SBLK) Price & Performance

Amylx Pharmaceuticals IncTrade
Star Bulk Carriers CorpTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Star Bulk Carriers Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.67 (market cap $2.64B), while Star Bulk Carriers Corp trades at $27.83 (market cap $3.09B). The key difference: Star Bulk Carriers Corp is the larger of the two by market cap, and Star Bulk Carriers Corp pays a 6.79% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXSBLK
Market Cap
$2.64B$3.09B
Sector
HealthIndustrials
52-Week High
$24.19$29.15
52-Week Low
$7.82$16.79
Enterprise Value
$2.39B$3.77B
Dividend Yield
6.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Star Bulk Carriers Corp

Star Bulk Carriers (SBLK) trades at $27.80, down 2.18% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported robust Q2 2026 results with net income of $144.9 million and declared a $0.90 dividend, reflecting operational strength. Revenue grew to $1.2 billion in 2026, with net profit margin expanding to 23.86%, while valuation ratios like P/E of 10.85 and EV/EBITDA of 7.46 suggest reasonable pricing. Recent news highlights termination of a vessel agreement with Diana Shipping, but operational updates remain positive.

SBLK presents a favorable outlook with earnings momentum, high dividend yield, and analyst buy consensus, though risks include dry bulk rate volatility and competitive pressures. The stock's fundamental health supports potential upside, but investors should weigh cyclical industry exposure against strong cash flow generation and balance sheet flexibility.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Star Bulk Carriers Corp

Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.

Read more on SBLK